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(AF). Methods: We collected a sequential, prospective, convenience sample of 
patients 50 years of age or older, admitted between December 2010 and March 
2013 diagnosed with ischemic stroke, excluding lacunar infarct, transitory cerebral 
ischemia, recurrent stroke or modified Rankin index greater than 2 prior to this 
episode. The presence of AF was sought with electrocardiogram and in some cases 
was studied with Holter. For a separate analysis, we matched for age and admission 
NIHSS score, in a 1:1 ratio, patients with and without AF. Variables measured in all 
cases were: age, gender, admission and discharge NIHSS, modified Rankin index, and 
CHA2DS2VASC score. Prospectively, we collected in-hospital resource use and costs 
incurred during the acute event. Exchange rate 1805 Colombian pesos = 1 American 
dollar (USD). Results: 166 patients were analyzed, 125 without and 41 with non-
valvular AF. For the paired analysis, we considered 37 patients with and 37 without 
AF. The average total cost of acute care for all stroke patients was USD$4,163 (SD 
$7,163) This value was USD$5,729 (SD $8,383) for patients with AF and for patients 
without AF USD$4,464 (SD $6,712). 15 patients (9%) died during the hospitalization, 9 
with AF (22%) and 6 without AF (5%). Of the matched group, 9 of the 37 patients with 
(24%) and 4 of those without (10%) required intensive care. ConClusions: 25% of 
large vessel ischemic stroke patients had AF. Treatment costs are higher in patients 
with AF, since they are older and with more severe strokes. Cost difference is reduced 
and shows no statistical significance when adjusted for age and stroke severity.
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objeCtives: Atrial fibrillation (AF) increases risk of thrombosis (e.g., ischemic stroke 
(IS), myocardial infarction (MI), systemic embolism (SE)). Conversely, thrombosis 
prevention increases bleed risk (e.g., gastrointestinal (GI) bleed, intracranial hemor-
rhage (ICH)). Assessment of the cost-effectiveness of novel anticoagulants (NOACs) 
relies on comparison of costs and outcomes before and after NOAC availability. 
However, published AF-specific costs have limited usefulness because they are out-
dated, limited to Medicare patients, and/or have not captured SE and MI. The objec-
tive of this study is to estimate the incremental costs of ‘events’ (IS, MI, SE, ICH, or GI 
bleed) in patients with AF. Methods: We conducted a matched (1:4), retrospective 
cohort study of patients ≥ 18 years old with incident, AF (ICD-9 427.31) between 2008 
and 2010, identified in the Truvan Health MarketScan® Commercial Claims and 
Medicare Supplemental and Coordination of Benefits Databases. Demographics, 
baseline health care costs, and comorbidities were assessed in the 12 months pre-
ceding AF diagnosis. Cases were defined as having one inpatient admission for an 
event after AF diagnosis followed by 12 months of continuous enrollment. Controls 
were AF patients without an event and 12 months of continuous enrollment after 
a ‘dummy’ event. Multivariate analyses were conducted to assess the incremental 
cost of each event at 30, 90, and 365 days. Results: We identified 1,788 cases and 
7,152 controls. For all events, at all time-points, overall health care costs were signifi-
cantly higher in cases than controls. The mean incremental cost (2012 US$) 30 days 
after the event was: IS-$20,710; MI- $32,535; SE-$15,754; ICH-$45,242; and GI bleed-
$14,823. At all time-points ICH was the most costly while SE and GI bleed were least 
costly. ConClusions: This study is the first to describe AF-specific incremental 
costs of multiple types of ischemic and bleeding events, prior to NOAC availability. 
Our results provide tools to assess the value of NOACs.
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objeCtives: The standard of care for patients with atrial fibrillation (AF) is war-
farin. However, warfarin use is limited by a narrow therapeutic range and docu-
mented risk of bleeding. This study aims to compare expected costs and clinical 
consequences of the usage of apixaban versus warfarin in the Mexican popula-
tion AF setting. Methods: A hypothetical patient cohort of 7,348 was evaluated, 
estimated from AF prevalence in 1,000,000 Mexicans. A decision tree model was 
developed considering annual costs and annual clinical consequences for both 
treatments. Effectiveness measures included the number of events for (1) stroke/
systemic embolism, (2) bleeding and (3) mortality. Event costs were estimated for 
each group. Under a conservative scenario, mortality events and INR monitoring 
were not considered. Rates for stroke, mortality and bleeding were extracted from 
the ARISTOTLE trial. Costs were estimated from a public health care perspective. 
Costs of treatment of events related to stroke and major bleeding corresponds to 
Diagnostic Related Groups published by IMSS. All costs are expressed in 2013 USD 
($1USD= $13MXN). Sensitivity analysis was performed. Results: Total number of 
events was lower for the apixaban cohort, the yearly stroke/systemic embolism 
events relative risk reduction was 21% versus the warfarin cohort (93 vs. 118 events, 
respectively), while the relative risk reduction of bleeding events was 31% (157 vs. 
227). Apixaban had an 11% relative risk reduction vs. warfarin in all cause mortal-
ity, with warfarin having 31 more mortality events for this cohort. The total cost of 
events for warfarin group was $600,849 for stroke/systemic embolism events and 
$742,011 for bleeding events while for apixaban group it was $476,924 and $511,483, 
respectively. Total costs of events were 26% higher for warfarin group ($1,342,860 vs. 
$988,407). ConClusions: The better clinical profile of apixaban when compared 
with warfarin has also important financial implications in terms of lower treatment 
costs for the events considered.
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objeCtives: The prevalence of venous thromboembolism (VTE) has been increas-
ing in China. However, the economic burden of the disease is not well understood. 
This study aims to estimate inpatient costs of VTE in China and identify key factors 
associated with costs. Methods: Hospitalizations with a diagnosis of VTE (includ-
ing deep vein thrombosis (DVT) or pulmonary embolism (PE)) were identified in 
a large hospital electronic medical record database that included 100% inpatient 
records from two tertiary hospitals between January 1st, 2010 and June 30th, 2013. 
Total costs per hospitalization as well as its components, pharmacy costs (all drug-
related costs) and non-pharmacy costs (all other costs), were estimated using hos-
pital billing data (in 2013 CNY) and converted to 2013 USD using an exchange rate 
of 6.12. Multivariate regressions were performed to assess factors associated with 
total hospitalization costs, including patient demographics, insurance status, VTE 
type, VTE diagnosis type, anticoagulant treatment, comorbidities, admission type, 
and surgical procedure. Results: A total of 1,047 VTE-related hospitalizations were 
included in the analysis. The mean age at hospitalization was 62.4 years and 54.1% 
of hospitalizations occurred to men. DVT accounted for 77.1% of the total hospitali-
zations. The average pharmacy, non-pharmacy, and total costs per hospitalization 
were CNY 9,820 (USD 1,604), CNY 19,294 (USD 3,153), and CNY 29,114 (USD 4,757), 
respectively. Diagnosis of PE (vs. DVT), anticoagulant treatments (vs. no anticoagu-
lant treatment), admission under critical condition, having surgical procedures, 
certain comorbidities, and VTE as secondary diagnosis were significantly associated 
with higher total costs per hospitalization (P < 0.05). ConClusions: In China, the 
inpatient costs of VTE are as high as 1.7 times of the average annual household 
income. Multiple factors, including VTE type, treatments, admission condition, etc., 
are associated with inpatient costs among VTE patients. Future studies are indicated 
to understand the cost variations.
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objeCtives: Heart failure (HF) ranks among the most costly diseases in the US, 
with hospitalizations being the driving force behind HF costs. This study sought 
to examine the most recent costs of hospitalizations among patients with sys-
tolic HF and commercial insurance in the US. Methods: This is a retrospective, 
observational study using a large, nationally representative commercial insurance 
claims database. Adult patients aged 18-64 years with ≥ 1 inpatient or ≥ 2 outpa-
tient diagnoses of systolic HF (ICD-9-CM 428.2x, 428.4x) in 1/1/2008-1/31/2013 and 
≥ 12-months of claims data prior to the first systolic HF diagnosis (index date) 
were included. Patients were followed until inpatient death or the end of the 
study period. Demographic and clinical characteristics and costs (health plan paid 
amount in 2013 dollars) of hospitalizations were summarized. Analyses focused 
on all-cause hospitalizations, hospitalizations with HF as a discharge diagnosis, 
and hospitalizations without HF but with other cardiovascular conditions as dis-
charge diagnosis. Results: A total of 26,848 patients met the study criteria (mean 
age 54 (SD 8.6); 63% male), with a mean follow up of 572 (SD 446) days. Comorbid 
conditions were common among systolic HF patients (hypertension: 34%; diabetes: 
26%; dyslipidemia: 21%; arrhythmias: 20%). During the study period, there was a 
total of 37,656 all-cause hospitalizations with a mean cost of $37,816 (SD $70,361), 
25,593 HF hospitalizations with a mean cost of $40,392 (SD $73,507), and 10,383 non-
HF CV hospitalizations with a mean cost of $34,823 (SD $66,773). ConClusions: 
Hospitalizations for heart failure pose a substantial economic burden to commercial 
payers in the US. Interventions targeted at preventing HF hospitalizations would 
alleviate the economic burden associated with HF.
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objeCtives: Approximately 23% of adults have varicose veins; 6% have advanced 
chronic venous disease characterized by hyperpigmentation, edema, and venous 
ulceration. Given limited real-world evidence, this study assessed varicose vein 
treatment patterns and corresponding outcomes, including costs, in the United 
States. Methods: A retrospective study was conducted using health care claims 
data from the Truven Health MarketScan database. Patients ≥ 18 years of age diag-
nosed with varicose veins between January 1, 2008 and June 30, 2012 were followed 
for 2 years post- diagnosis. Patients were classified into cohorts based on the pres-
ence and type of invasive treatment, and characterized by baseline symptomatic 
(ICD-9 codes: 454.0x, 454.1x, 454.2x, 454.8x) or asymptomatic (ICD-9 454.9x) disease, 
demographics and Thomson-Reuters Disease Stage. Retreatment rates, health care 
utilization and costs were compared across cohorts. Results: A total of 144,098 
patients met the study criteria. Mean age was 57 years, and 71% were female. 
Approximately 70% of patients received active surveillance/compression therapy; 
the remainder received invasive therapy (laser ablation, radiofrequency ablation, 
sclerotherapy, or surgery). Compared to the surveillance cohort, patients receiving 
invasive therapy were younger (53 years vs 58 years, p< 0.0001) and more likely to be 
female (76.5% vs 68.3%; p< 0.0001) and have symptomatic disease (81.2% vs 63.9%; 
p< 0.0001). Among those with invasive therapy, 25% received retreatment, with asso-
ciated 2-year treatment-specific costs around $6,800. Total 2-year costs for active 
surveillance (~$17,000) were lower compared to those with invasive therapies, espe-
cially compared to those with retreatment (~$19,000) (p< 0.0001). ConClusions: 
About 30% of patients with diagnosed varicose veins received invasive therapy; they 
were more likely to be younger, female and symptomatic. About 25% of patients 
receiving invasive therapy were re-treated within 6 months of diagnosis, with high-
